Eden helps marine protein-based MRSA drug candidate to next stage
Eden Biodesign in Liverpool, UK, has been selected by leading marine biotechnology company, Aquapharm BioDiscovery, in Oban, UK, to develop AQP001, a novel protein drug candidate.
AQP001 is a natural marine product identified by Aquapharm BioDiscovery scientists as a broad spectrum antibacterial agent active against bacteria resistant to standard antibiotics, including MRSA.
Eden Biodesign will use its expertise in protein drug development and manufacturing to assist Aq-uapharm BioDiscovery in large scale production of AQP001 for clinical development.
Dr Crawford Brown, ceo of Eden Biodesign said: "To our knowledge, this is the first instance of a protein pharmaceutical derived from a marine organism entering commercial development and we are delighted to utilise our expertise and experience in support of Aquapharm BioDiscovery."
Aquapharm Biodiscovery has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the new National Biomanufacturing Centre operated by Eden Biodesign on behalf of NWDA.